Be part of the knowledge.™

Oncology and Hematology

966

LikeLikedUnlike

271-285 of 285

Utilization and Management of Antibody-Drug Conjugates in Metastatic Breast Cancer: The Relationship Between ADCs and HER2
CME/CE
Utilization and Management of Antibody-Drug Conjugates in Metastatic Breast Cancer: The Relationship Between ADCs and HER2
- William J. Gradishar, MD
  Peer
- Javier Cortes, MD, PhD
  Peer
- Hope S. Rugo, MD, FASCO
  Peer
TROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use
CME/CE
TROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use
- Benjamin Levy, MD
  Peer
- Rebecca Heist, MD, MPH
  Peer
- Peter Bela Illei, MD
  Peer
MinuteCE®
A Deep Dive into the Management of AEs Associated with ADCs
- Jaffer Ajani, MD
  Peer
- Justin Gainor, MD
  Peer
- Sara A. Hurvitz, MD, FACP
  Peer
- Gopa Iyer, MD
  Peer
HER2-Directed ADCs in Breast Cancer
CME/CE
HER2-Directed ADCs in Breast Cancer
- Sara A. Hurvitz, MD, FACP
  Peer
TROP2-Directed ADCs in Breast Cancer
MinuteCE®
TROP2-Directed ADCs in Breast Cancer
- Sara A. Hurvitz, MD, FACP
  Peer
HER3-Directed ADCs in Breast Cancer
MinuteCE®
HER3-Directed ADCs in Breast Cancer
- Sara A. Hurvitz, MD, FACP
  Peer
advertisement
HER2-Directed ADCs in Lung Cancer
MinuteCE®
HER2-Directed ADCs in Lung Cancer
- Justin Gainor, MD
  Peer
TROP2-Directed ADCs in Lung Cancer
MinuteCE®
TROP2-Directed ADCs in Lung Cancer
- Justin Gainor, MD
  Peer
HER3-Directed ADCs in Lung Cancer
MinuteCE®
HER3-Directed ADCs in Lung Cancer
- Justin Gainor, MD
  Peer
HER2-Directed ADCs in Gastric Cancer
MinuteCE®
HER2-Directed ADCs in Gastric Cancer
- Jaffer Ajani, MD
  Peer
Nectin-4-Directed ADCs in Bladder Cancer
MinuteCE®
Nectin-4-Directed ADCs in Bladder Cancer
- Gopa Iyer, MD
  Peer
TROP2-Directed ADCs in Bladder Cancer
MinuteCE®
TROP2-Directed ADCs in Bladder Cancer
- Gopa Iyer, MD
  Peer
advertisement
A Novel Therapeutic Approach in Myeloid Malignancies: Targeting the Neddylation Pathway
CME/CE
A Novel Therapeutic Approach in Myeloid Malignancies: Targeting the Neddylation Pathway
- Jennifer Caudle, DO, FACOFP
  Peer
- Mikkael A. Sekeres, MD, MS
  Peer
- Sara M. Tinsley, PhD, ARNP, AOCNP
  Peer
0.50 credits
Unresectable HCC: An Emerging Era of Combination Therapy – A Clinical Convergence^®
CME/CE
Unresectable HCC: An Emerging Era of Combination Therapy – A Clinical Convergence^®
- Richard S. Finn, MD
  Peer
- Amit Singal, MD, MS
  Peer
- Mark Yarchoan, MD
  Peer
Immunotherapy: Changing Patient Outcomes in SCLC
CME/CE
Immunotherapy: Changing Patient Outcomes in SCLC
- Leora Horn, MD, MSc
  Peer

Program Chapters

Segment Chapters

Playlist:

Recommended